But there aren’t many studies on the long-term effects of TRT (for example, over decades). If you don’t have these health concerns, TRT is generally safe. This is why healthcare providers do extensive evaluations and tests before approving the use of TRT.
Several common tests more accurately detect prostate cancer cases by also measuring subtypes of free PSA, including the Prostate Health Index (measures a fragment called −2proPSA) and 4K score (measures intact free PSA). Benign prostatic hyperplasia, prostate infection, recent ejaculation, and some urological procedures can increase PSA levels; taking 5α-reductase inhibitors can decrease PSA levels. Metastases can damage the bones around them, and around a quarter of those with metastatic prostate cancer develop a bone fracture. Advanced prostate tumors can metastasize to nearby lymph nodes and bones, particularly in the pelvis, hips, spine, ribs, head, and neck. More than half of men over age 50 experience some form of urination problem, typically due to issues other than prostate cancer such as benign prostatic hyperplasia (non-cancerous enlargement of the prostate). The invention of hormone therapies for prostate cancer was recognized with the 1966 Nobel Prize to Charles Huggins and the 1977 Prize to Andrzej W. Schally.
Eventually, a tumor can grow large enough to invade nearby organs such as the seminal vesicles or bladder. Men whose cancer has metastasized to a nearby part of the body (around 15% of diagnoses) have poorer prognoses, with five-year survival rates of 60–80%. These are typically treated with appetite-increasing drugs – megestrol acetate or corticosteroids – antiemetics, or treatments that focus on underlying gastrointestinal issues. The first line of treatment typically involves GnRH agonists like leuprolide, goserelin, or triptorelin by injection monthly or less frequently as needed. Both for cancer progression outcomes and surgical side effects, the skill and experience of the individual surgeon doing the procedure are among the greatest determinants of success. IMRT is given over several sessions, with treatments repeated five days per week for several weeks.
The prostate is the only male accessory gland that occurs in cetaceans, consisting of diffuse urethral glands surrounded by a very powerful compressor muscle. In some marsupial species, the size of the prostate gland changes seasonally. The structure of the prostate varies, ranging from tubuloalveolar (as in humans) to branched tubular. The presence of a functional prostate in monotremes is controversial, and if monotremes do possess functional prostates, they may not make the same contribution to semen as in other mammals.
Prostate cancer that is only present in the prostate is often treated with either surgical removal of the prostate or with radiotherapy or by the insertion of small radioactive particles of iodine-125 or palladium-103, called brachytherapy. These genetically engineered mouse models typically use a Cre recombinase system to disrupt tumor suppressors or activate oncogenes specifically in prostate cells. Researchers can either surgically implant human prostate tumors into immunocompromised mice (a technique called a patient derived xenograft), or induce prostate tumors in mice with genetic engineering. Research into prostate cancer relies on a number of laboratory models to test aspects of the disease. This places prostate cancer 10th among 18 common cancer types in funding per cancer death, and 9th in funding per disability-adjusted life year lost. From 2016 to 2020, more than $1.26 billion was invested in prostate cancer research, representing around 5% of global cancer research funds. After additional trials in 2015, docetaxel use was extended to those with castration-sensitive prostate cancer.
No drug or vaccine is approved by regulatory agencies for the prevention of prostate cancer. T3 is for tumors that grow beyond the prostate – T3a for tumors with any extension outside the prostate; T3b for tumors that invade the adjacent seminal vesicles. Ten to twelve samples are taken from several regions of the prostate to improve the chances of finding any tumors. Hardening of the prostate can also be due to benign prostatic hyperplasia; around 20–25% of those with abnormal findings on their rectal exams have prostate cancer. Major national health organizations offer differing recommendations, attempting to balance the benefits of early diagnosis with the potential harms of treating people whose tumors are unlikely to impact health..|Alternatively, the doctor may recommend a prostate biopsy without further testing. If the PSA level continues to rise—especially if it rises quickly—or if a lump is detected during a DRE, the doctor may recommend additional tests. If the PSA level is still elevated, the doctor may recommend continued observation with repeat PSA tests along with digital rectal exams (DREs) to watch for any changes over time. People are generally recommended to wait until any conditions that can change PSA level resolve before they have testing and to avoid activities that may raise the PSA level for 2 days before testing. Vigorous exercise (such as cycling) and ejaculation can also increase the PSA level transiently.|GnRH agonists cause a brief rise in testosterone levels at treatment initiation, which can worsen disease in people with significant symptoms of metastases. Various drugs are used to lower androgen levels by blocking the synthesis or action of testosterone, the primary androgen. People with high or rising PSA levels are often offered another round of radiation therapy directed at the former tumor site. At least half of men remain on active surveillance, never requiring more direct treatment for their prostate tumors. This program continues until increases in PSA levels, Gleason grade, or tumor size indicate a higher-risk tumor that may require intervention.|Certain existing health conditions make it unsafe, like prostate cancer and heart failure. Testosterone replacement therapy (TRT) is an option for men who have low testosterone levels due to male hypogonadism. Systemic chemotherapy for prostate cancer was first studied in the 1970s.|Interestingly, 2 of the included studies examined the effect of testosterone replacement in men with type 2 diabetes mellitus and whereas one22 found that IM testosterone did not have an effect on insulin resistance or dyslipidemia, the other20 showed that transdermal replacement had a beneficial effect on insulin resistance and lipid levels. Only 3 studies provided data with respect to the development of prostate cancer (Table 2). Forest plot comparing the number of patients with elevated PSA level after treatment between patients receiving testosterone treatment via transdermal, oral (PO) and intramuscular (IM) routes versus control treatments. Forest plot comparing PSA level change between patients receiving testosterone treatment via transdermal, oral (PO) and intramuscular (IM) routes versus control treatments. Nine of the 15 studies provided complete data regarding PSA levels before and after treatment (Figure 2). For the difference of PSA levels between before and after treatment, the difference in means with 95% confidence interval (CI) between testosterone and control treatments was calculated. The systematic review and meta-analysis aimed to determine the effect of testosterone replacement therapy on PSA levels.|The prostate is an accessory gland of the male reproductive system and a muscle-driven mechanical switch between urination and ejaculation. Several prostate immortalized cell lines are widely used, namely the classic lines DU145, PC-3, and LNCaP, as well as more recent cell lines 22Rv1, LAPC-4, VCaP, and MDA-PCa-2a and −2b. The observation that the testicles (and the hormones they secrete) influence prostate size was made as early as the late 18th century via castration experiments in animals. In the 1970s, Willet Whitmore pioneered an open surgery technique where needles of Iodine-125 were placed directly into the prostate. By the 1960s, this was often combined with hormone therapy to improve the potency of therapy.}
Cancer that does not respond to hormonal treatment, or that progresses after treatment, might be treated with chemotherapy such as docetaxel. Cancer that has spread to other parts of the body is usually treated also with hormone therapy, to deprive a tumour of sex hormones (androgens) that stimulate proliferation. Uncommonly, such cancers may cause weight loss, retention of urine, or symptoms such as back pain due to metastatic lesions that have spread outside of the prostate.

Gender: Female

Social links